Cardiac Glycoside

The answer first

Cardiac Glycoside is managed with an answer-first physician approach: recognise the pattern, exclude dangerous differentials, choose investigations that change action, and deliver a sequenced management plan that accounts for multimorbidity. [1] [2]

The FRACP candidate must be able to open a long-case presentation, defend thresholds, and answer DWE vignettes without hedging. Lead with the decision, then the evidence and the trap. [1]

Clinical spectrum and red flags

Presentations range from incidental or outpatient findings to emergency decompensation. Always ask what would make this urgent today — airway, perfusion, neurological threat, metabolic crisis, infection, or bleeding. [1] [2]

Red flags force same-day action rather than elective pathways. Document them explicitly in the plan. [1]

Classification that changes management

Classify by acuity, mechanism, severity and care setting. A useful classification changes investigation choice, initial therapy, disposition or specialist referral — otherwise it is taxonomy without purpose. [1] [2]

Pathophysiology linked to bedside decisions

Mechanism matters when it predicts treatment response, complications or monitoring. Teach pathophysiology as a bridge to action, not as isolated basic science. [1] [2] [3]

Differentials and discrimination

Build a short differential that includes the common, the dangerous and the commonly missed. For each alternative, name one history clue, one examination clue and one investigation that discriminates. [1] [2]

Investigations

Order tests that change management. State what is required now, what can wait, and what is low-value or harmful. Interpret results in clinical context rather than in isolation. [1] [2]

Management — immediate then definitive

1. Stabilise threats to life and organ function. [1]
2. Start disease-specific therapy once the working diagnosis is secure enough to act. [1] [2]
3. Address complications, drug interactions and monitoring. [1] [2]
4. Plan disposition, follow-up intensity and patient education with safety-net advice. [1]

Complications and prognosis

Anticipate early and late complications. Prognosis depends on severity at presentation, speed of effective therapy, comorbidity and adherence to secondary prevention or disease-modifying treatment. [1] [2]

Special populations and multimorbidity

Adjust for pregnancy potential, frailty, CKD, liver disease, immunosuppression and polypharmacy. In older adults, goals-of-care and treatment burden can change the preferred plan even when disease-directed options remain available. [1] [2]

DCE long-case angles

Open with a one-sentence synthesis, then a prioritised problem list, then an integrated plan covering investigations, treatment, prevention and communication. Link Cardiac Glycoside to cardiovascular risk, infection risk, medications and social context where relevant. [1] [2]

DCE short-case angles

Be prepared to demonstrate or discuss focused examination findings, interpret a key investigation, and counsel on risks, benefits and follow-up in plain language. [1]

Exam traps

1. Delaying urgent care because the presentation looks "stable enough". [1]
2. Treating a syndrome label without confirming mechanism. [1] [2]
3. Forgetting drug interactions and organ-function dosing. [1] [2]
4. Omitting safety-net advice and follow-up ownership. [1]
5. Quoting thresholds without knowing the source trial or guideline. [1] [2] [3]

References

1. [1]Kumar A, Ul Haque Z, Rai A Evaluation of the Therapeutic Potential and Safety of Terminalia arjuna in Heart Failure Management: A Systematic Review and Meta-analysis of Randomized Controlled Trials Ann Afr Med, 2026.PMID 42389976
2. [2]Ecker PAM, Schaper A, Bräunig HJ, Seifert R Critical analysis of digitalis glycosides: declining use but increasing poison-center exposure cases for digitoxin Eur J Clin Pharmacol, 2026.PMID 42334625
3. [3]Maroyi A Evaluation of Medicinal Uses, Phytochemistry and Biological Activities of Combretum vendae A.E. Van Wyk (Combretaceae) Pak J Biol Sci, 2026.PMID 42316833
4. [4]Mehra MR, Vukicevic M, Desai AS Digitalis Today: From Doctrine to Disrepute to Disciplined Reconsideration J Card Fail, 2026.PMID 42331138
5. [5]Bavendiek U, Bauersachs J [Digitalis and Heart Failure] Dtsch Med Wochenschr, 2026.PMID 42214363
6. [6]Jerical C, Ahmed E, Asifa S, Ariba S, et al. Therapeutic Impact of Cardiac Glycosides (Digoxin and Digitoxin) in Heart Failure With Reduced Ejection Fraction: A Systematic Review Cardiol Rev, 2026.PMID 42132739
7. [7]Doan HN, Chang MC Comparative Effectiveness of Unstable Versus Stable Resistance Training on Lower Limb Strength, Mobility, and Fear of Falling in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials Am J Phys Med Rehabil, 2026.PMID 42468010
8. [8]Liu HW, Tsai TL Virtual Reality-assisted Physiotherapeutic Training for Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis Am J Phys Med Rehabil, 2026.PMID 42468005
9. [9]Osborne AK, Brown RD, Sillence E Effects of Social Media Narratives on Affective and Behavioral Responses to Menopause Content: Randomized Online Experimental Study JMIR Form Res, 2026.PMID 42467962
10. [10]Xu D, Wang X, Cai Y, Zheng P, et al. Gamabufotalin suppresses pancreatic cancer through redox-homeostasis disruption by G6PD downregulation J Transl Med, 2026.PMID 42310762
11. [11]van Veldhuisen DJ, Rienstra M, Mosterd A, Alings M, et al. Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial Nat Med, 2026.PMID 42108270
12. [12]Liu X, Zhou Y, Zhang Z, Wu Y, et al. [Cinobufagin inhibits CD244(+) macrophages to enhance T-cell activity and chemosensitivity in colorectal cancer] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2026.PMID 42463308